Rock Springs Capital Management LP Acelrx Pharmaceuticals Inc Transaction History

Rock Springs Capital Management LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	BUY	$0.28 - $0.61 $924 - $2,013	3,300 Added 0.05%	6,329,202 $1.81 Million
Q4 2021 Feb 14, 2022	BUY	$0.49 - $1.02 $1.23 Million - $2.56 Million	2,506,500 Added 65.63%	6,325,902 $3.54 Million
Q3 2021 Nov 15, 2021	BUY	$0.93 - $1.51 $28,499 - $46,273	30,645 Added 0.81%	3,819,402 $3.9 Million
Q2 2021 Aug 16, 2021	BUY	$1.03 - $1.7 $3,399 - $5,610	3,300 Added 0.09%	3,788,757 $5.23 Million
Q1 2021 May 17, 2021	BUY	$1.25 - $2.77 $3,750 - $8,310	3,000 Added 0.08%	3,785,457 $6.44 Million
Q4 2020 Feb 16, 2021	BUY	$1.18 - $1.98 $10,468 - $17,566	8,872 Added 0.24%	3,782,457 $4.69 Million
Q3 2020 Nov 16, 2020	BUY	$1.01 - $1.81 $3.81 Million - $6.83 Million	3,773,585 New	3,773,585 $5.36 Million

Ticker ACRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 7,366,600
Market Cap $8.32M
Description
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed ...

Get notified when there are updates to the investment portfolio of Rock Springs Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Rock Springs Capital Management LP with notifications on news.